Loading…
The patent involves the use of exosomes from stem cell programmed myeloid cells.
Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled "SUPPRESSION OF DIABETES USING EXOSOMES FROM STEM CELL PROGRAMMED MYELOID CELLS". This development signifies a significant advancement in the company's biotechnology portfolio.
The patent, once granted, will provide Creative Medical Technology Holdings with exclusive rights to utilize this innovative approach for diabetes suppression, potentially opening new avenues for treatment and research in the field of biotechnology.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.